homocysteine at the crossroads: vitamin status and disease prevention

Homocysteine At The Homocysteine At The Crossroads:Crossroads:

Vitamin Status and Disease Vitamin Status and Disease PreventionPrevention

Dr. Samuel N. Grief, MD, FCFP

University of Illinois at Chicago Family Medicine

Chair, Panel on Homocysteine and Screening/Treatment Recommendations

OUTLINEOUTLINE

Homocysteine and its metabolism. Homocysteine and nutrition: The vitamin

connection. Food sources of vitamins Betaine, B12, and

Folate. Homocysteine and its link to various diseases. Recommendations regarding homocysteine

screening and treatment.

OBJECTIVESOBJECTIVES

Based on scientific evidence, attending physician will be able to:

1. Define homocysteine 2. Outline homocysteine metabolic pathway 3. List metabolic and vitamin influences on

homocysteine level 4. Identify risk factors for elevated homocysteine

level 5. Determine whether to screen for, and treat,

elevated homocysteine level

Homocysteine has been confirmed in many independent studies to be a risk factor for cardiovascular disease.

References: Eikelboom JW, Lonn E, et.al. HCY and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131(5):363-375. Singh H. Selections from current literature: HCY: a modifiable risk factor for cardiovascular disease. Fam Pract 1997;14(4):335-9. Refsum H, Ueland PM, Nygard O, Vollset SE. HCY and cardiovascular disease. Annu Rev Med. 1998;49:31-62.

Etiology of Cardiovascular Etiology of Cardiovascular DiseaseDisease

Traditional risk factors for coronary artery disease such as smoking, hypertension, diabetes, and dyslipidemias can only explain approximately two thirds of observed clinical events.

Other factors/biochemical markers to consider include: CRP Homocysteine Other?

Reference: Maxwell SR, Coronary Artery Disease-free radical damage, antioxidant protection and the role of HCY. Basic Res Cardiol. 2000;95 Supple 1:165-71.

Homocysteine and Homocysteine and Cardiovascular DiseaseCardiovascular Disease

Increased incidence and progression of CAD in patients with diabetes when homocysteine levels are >11.21 micromol/l was found in a study of Polish men aged <55 (mean age 49.5 +/- 5.7 years).

Reference: Skibinska E, Sawicki R, et.al. Kardiol Pol. 2004 Mar;60(3):197-205.

Homocysteine and Endothelial Homocysteine and Endothelial EffectsEffects

The mechanism by which homocysteine exerts its cardiovascular disease effects are now being elucidated. Many authorities have studied this link. The working hypothesis is that elevated homocysteine levels:

1. promote oxidant injury to the vascular endothelium 2. impairs endothelium-dependent relaxation 3. alters the coagulant properties of blood References: Ozdemir R, Barutcu I, et.al. Vascular Endothelial Function and Plasma Homocysteine Levels in Behcet’s Disease, Am J Cardiol 2004;94:522-525. Austin RC, Lentz SR, Werstuck GH. Role of HyperHCYemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004 Jul;11 Supple 1:S56-

64.

Homocysteine and Endothelial Homocysteine and Endothelial EffectsEffects

Other theories include:a) Elevated homocysteine levels release extracellular superoxide dismutase from the endothelial wall, causing a higher likelihood of atherosclerotic changes to the blood vessels

b) Moderate HyperHCYemia may develop secondary to cellular immune activation, usually in response to a chronic disease condition c) Hyperhomocysteinemia decreases bioavailability of nitric oxide, thus decreasing endothelial vasodilator function. References:Nihei S, Tasaki H, et.al. HyperHCYemia is associated with human coronary atherosclerosis through the reduction of the ratio of endothelium-bound to basal extracellular superoxide dismutase. Circ J. 2004 Sep;68(9):822-8

Schroecksnadel K, Frick B, Winkler C, et.al. HyperHCYemia and immune activation. Clin Chem Lab Med. 2003;41:1438-1443.

EpidemiologyEpidemiology

Prevalence of hyperhomocysteinemia is not insignificant: 1. general population: 5 - 10% 2. elderly population: 30 - 40% 3. pts with vascular disease: 20 - 40%.

References: Annu Rev Med 1998;49:31-62. HCY and cardiovascular disease. Refsum H, Ueland PM, et.al. JAMA 1993;270:2693-8. Vitamin status and intake as primary determinants of HCYemia in an elderly population. Selhub J, Jacques PF, et.al.

Jacques PF, Bostom AG, Wilson PW, et.al. Determinants of plasma total HCY concentration in the Framingham Offspring cohort. Am J Clin Nutr. 2001;73:613-

621.

Homocysteine and diseaseHomocysteine and disease

Homocysteine elevation is also known to be strongly associated and linked to several other medical conditions, including:

osteoporosis cognitive impairment and decline increased prenatal complications to women and unborn

children chronic kidney disease other conditions References: Kidney Int. 2004 Jul;66(1):338-47. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-

reactive protein. Busch M, Franke S, et.al. Clin Chem. 2004 Aug 19. Screening for Serum Total HCY in Newborn Children. Refsum H, Grindflek AW, Ueland PM, et.al

HOMOCYSTEINEHOMOCYSTEINE

Homocysteine, a sulfur containing amino acid, is formed from methionine, an essential amino acid found in many animal and plant foods. Methionine is especially abundant in animal and cereal proteins.

Reference: Aleman G, Tovar AR, Torres N. Homocysteine metabolism and risk of cardiovascular disease: Importance of the nutritious status in folic

acid, vitamins B6 and B12. La Revista de Investigacion Clinica. Vol.53, Issue 2, March-April 2001, pp. 141-151.

Homocysteine MetabolismHomocysteine Metabolism

Homocysteine is removed either by its irreversible conversion to cysteine (transsulfuration) or by remethylation to methionine.

There are two separate remethylation reactions, catalyzed by betaine:homocysteine methyltransferase and methionine synthase, respectively.

Homocysteine and Nutrition:Homocysteine and Nutrition: The Vitamin ConnectionThe Vitamin Connection

The reactions that remove homocysteine are dependent upon B vitamin status, as both the transsulfuration enzymes contain pyridoxal phosphate (B6), while methionine synthase contains cobalamin (B12), is copper-dependent, and receives its methyl group from the folic acid one-carbon pool.

Reference: Brosnan JT, Jacobs RL, et.al. Methylation demand: a key determinant of homocysteine metabolism. Acta Biochim Pol. 2004;51(2):405-

13.


It is estimated that in about two-thirds of cases of hyperhomocysteinemia, vitamin deficiency is the primary cause.

Reference: Selhub J, Jacques PF, et.al. Vitamin Status and intake as primary determinants of HCYemia in an elderly population. JAMA 1993; 270: 2693-

2698.

Fig. 2 - Physiological determinants of total homocysteine levels

Vitamin B12 and Vitamin B12 and HomocysteineHomocysteine

Vitamin B12 is found in foods of animal origin. Vitamin B12 status has been studied in different populations,

especially vegetarians.

Evidence confirms: low vitamin B12 levels predispose to elevated homocysteine levels.

References: Waldmann A, Koschizke JW, et.al. HCY and cobalamin status in German vegans. Public Health Nutr. 2004 May;7(3):467-72.

Flood VM, Webb KL, Smith W, et.al. Prevalence of low serum folate, red cell folate, serum vitamin B12 and elevated HCY. Asia Pac J Clin Nutr. 2004;13(Suppl):S85.

Food sources of Vitamin B12Food sources of Vitamin B12

BEST FOOD SOURCES OF VITAMIN B12

FOOD PORTION SIZE AMOUNT (MCG)

Liver 100 grams 70.58Seafood 100 grams 6.88 Salmon 100 grams 2.80Beef Hamburger 100 grams 2.50Eggs 100 grams 1.11___________________________________________________________MCG: MicrogramsNB: 100 grams=3.5 ounces

FOLATEFOLATE

Folate, aka folic acid, found in numerous foods, is a water-soluble B-vitamin and enzymatic co-substrate for the synthesis of methionine from homocysteine.

Folic acid deficiency is the most common cause of elevated HCY levels.

Reference: Jacques PF, Selhub J, et.al The effect of folic acid fortification on plasma folate and total HCY concentration. N Engl J Med 1999;13:1449-1454.

FolateFolate

The U.S. Food and Drug Administration’s implementation of mandatory fortification of grains and cereals with folic acid on January 1, 1998 is a direct result of research studies confirming folate’s HCY-lowering effects, as well as studies linking low folate levels with an increased incidence of neural tube defects.

References: Tucker KL, Selhub K, et.al. Dietary intake pattern related to plasma folate and HCY concentrations in the Framingham Heart Study. J Nutr 1996;126:3025-

3031. Food and Drug Administration. Food Standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Federal

Register. 1996;61(44):8781-97.

Riddell, LJ, Chisholm A, et.al. Dietary strategies for lowering HCY concentrations. Am J Clin Nutr. 2000; 71(6): 1448-54.

Vitamins and Food sourcesVitamins and Food sources

Folic acid - Green leafy vegetables (e.g. spinach, broccoli), legumes (e.g. lentils, chick peas, lima beans), orange

Vitamin B6 - Meat, poultry, fish, green leafy vegetables, legumes, seeds, potatoes, cantaloupe, milk, egg yolks, cereals, grains, wheat, wheat germ

Vitamin B12 - Beef, poultry, fish (particularly crab, oyster, salmon and herring), liver, kidney, soy, fruit juice, dairy products, egg yolks, fortified cereals, breads


Betaine, a choline derivative, is important because of its role in methyl group donation to homocysteine to form methionine.

Reference: Zeisel SH, Mar MH, et.al. Concentrations of choline-containing compounds and betaine in common foods. J Nutr. 2003 May;133(5): 1302-7.

Many foods are rich in BetaineMany foods are rich in Betaine

Studies confirm betaine’s ability to reduce homocysteine levels in the face of excess methionine intake.

References:

Steenge GR, Verhoef P, Katan MB. Betaine supplementation lowers plasma HCY in healthy men and women. J Nutr. 2003 May;133(5):1291-5.

Olthof MR, van Vliet, et.al. Low dose betaine supplementation leads to immediate and long term lowering of plasma HCY in healthy men and women. J

Nutr. 2003 Dec;133(12):4135-8.

Choline and Betaine Food Sources Amount (mg/100g food) Wheat Bran 1339

Wheat Germ 1293Spinach 645Beef Liver 418

Chicken Liver 290 Eggs 251 Pretzels 237 Shrimp 218 Wheat Bread 201 Bacon 125 Dried Soybeans 116 Pork 103

Food sources of BetaineFood sources of Betaine

VISP STUDYVISP STUDY

In the recently completed Vitamin Intervention for Stroke Prevention (VISP) study, Toole, et.al. investigated the homocysteine-lowering effects of B vitamins in over 40,000 men with established history of cerebrovascular accidents.

Reference: Toole JF, Malinow MR, Chambless LE, et.al. Lowering HCY in pts. With ischemic stroke to prevent recurrent stroke, MI, and death: the Vitamin

Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.


The VISP randomized controlled trial was undertaken to assess whether reducing HCY levels by vitamin supplementation would reduce risk of recurrent strokes, CHD, and death.

Reference: Toole JF, Malinow MR, Chambless LE, et.al. Lowering HCY in pts. With ischemic stroke to prevent recurrent stroke, MI, and death: the Vitamin

Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.


High-dose vitamin supplementation participants received:

25mg of pyridoxine 400mcg of cobalamin 2.5mg of folic acid low-dose was 200mcg, 6mcg, and 20mcg, respectively.

Reference: Toole JF, Malinow MR, Chambless LE, et.al. Lowering HCY in pts. With ischemic stroke to prevent recurrent stroke, MI, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.

RDA for Vitamins B6, B12 and RDA for Vitamins B6, B12 and FolateFolate

Vitamin B6 2 mgVitamin B12 6 mcg Folate 400 mcg


Even though a mean reduction of HCY in the high-dose vitamin supplementation group of 2 micromol/l greater than in the low-dose group was achieved, no significant effect on the above end points occurred.



The results did not confirm a reduction in recurrent strokes in study patients, however, the homocysteine-lowering effects of folic acid, vitamin B6 and vitamin B12 were confirmed.


SCREENING AND TREATMENT RECOMMENDATIONS FOR SCREENING AND TREATMENT RECOMMENDATIONS FOR

HOMOCYSTEINEHOMOCYSTEINE

In 2000, the Canadian Task Force on Preventive Health Care concluded that there was a link between total HCY levels and CAD based on cohort and case-control studies, but found the evidence insufficient to recommend for or against HCY screening in both the general and high-risk populations.

Reference: CMAJ.2000 Jul 11;163(1):21-9. Preventive health care, 2000 update: screening and management of hyperHCCYemia for the prevention of CAD evens. The

Canadian Task Force on Preventive Health Care. Booth GL, Wang EE.

SCREENING AND TREATMENT RECOMMENDATIONS FOR SCREENING AND TREATMENT RECOMMENDATIONS FOR HOMOCYSTEINEHOMOCYSTEINE

An expert panel led by Refsum reviewed multiple, well-designed, randomized controlled trials and concluded the following:

A) Vitamin “B” intake directly impacts the level of homocysteine B) Folate deficiency is a strong determinant on homocysteine levels C) Coffee consumption may very well increase total homocysteine levels D) Unhealthy lifestyle and poor diet is a cause of moderately high levels of

homocysteine (15-30 micromol/l).

Reference: Refsum H, Smith DA, et.al. Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion. Clin Chem 2004; 50:

3-32.

HOMOCYSTEINE IS AT THE CROSSROADS OF HOMOCYSTEINE IS AT THE CROSSROADS OF VITAMIN STATUS (B6, B12, FOLATE) VITAMIN STATUS (B6, B12, FOLATE)

Screening for HCY may indirectly assess a patient’s vitamin B6, B12 and folate status, thus offering a useful window into the patient’s nutrition profile.

Total homocysteine measurements are now recommended to screen for vitamin deficiency in both the general and high risk populations.

Reference: Clarke R, Refsum H, et.al. Screening for vitamin B12 and folate deficiency in older persons. Am J Clin Nutr 2003; 77: 1241-7.

Screening RecommendationsScreening Recommendations

HCY evaluation is now recommended for the following high risk populations:

age 65 years and over with or without co-morbid conditions in patients with any of the following medical conditions, including: diabetes smoking history established cardiovascular disease or multiple cardiovascular risk factors renal disease nutritional deficiencies cognitive disorders References: Nygard O, Nordrehaug JE, Refsum H, et.al. Plasma HCY levels and mortality in patients with CAD. N Engl J Med. 1997;337:230-236. Fallest-Strobl PC, Koch DD, et.al. HCY: A New Risk Factor for Atherosclerosis. American Family Physician. Oct.15, 1997. Vol.56, No.6. Malinow MR, Bostom AG, Krauss RM. HCY, diet, and cardiovascular diseases: a statement for health care professionals from the Nutrition Committee,

American Heart Association. Circulation 1999;99:178-182. Nilsson M. Cobalamin and folate deficiency. Paradigm shift in screening. Rondel 2004;18. http://www.rondellen.net.

Therapeutic GoalsTherapeutic Goals

Target plasma HCY levels of <10 micromol/l are now being recommended by various medical authorities.

References: Stanger O, Herrmann W, et.al. Clinical use and rational management of HCY, folic acid, and B vitamins in cardiovascular and thrombotic disease. Z

Kardiol.2004 Jun; 93(6):439-53. Malinow MR, Bostom AG, et.al. Homocysteine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee,

American Heart Association. Circulation 1999; 99: 178-82.

Ubbink JB. What is a desirable homocysteine level? In: Carmel R, Jacobsen DW, eds. Homocysteine in health and disease. Cambridge, UK: Cambridge

University Press, 2001: 485-90.

TABLE 3: Homocysteine level relation to overall mortality and CAD-related death.

Some experts suggest that target homocysteine levels should be realistically below values where risk for cardiovascular disease substantially increases. Reference:Booth, G. CMAJ. 2000 July; 163(1): 21-29.

High Risk Population a

Yes No

Screen for HCY Do not screen for HCY

Level > 10 micromol/l Level < 10 micromol/l Continue monitoring/treating other medical conditions

Treatment No treatment

aHigh risk population defined in “Recommendations regarding HCY screening” section.

Vitamins B6, B12, Folate May recommend MVI

Why Rx Vitamins?Why Rx Vitamins?

Appropriate vitamin awareness, knowledge of Rxing vitamins, and ability to recommend nutritional sources of vitamins will become more critical for physicians to master as the future of medicine changes from a diagnostic/therapeutic mode to a more preventive/holistic style.

RDA for Vitamins B6, B12 and RDA for Vitamins B6, B12 and FolateFolate

Vitamin B6 2 mgVitamin B12 6 mcg Folate 400 mcg

Treatment RecommendationsTreatment Recommendations

Add to the overall treatment plan of your high-risk patient a B-complex vitamin containing, at a minimum, the following B-vitamins:

Folic acid 1.0 mg Vitamin B6 10mgVitamin B12 1.0mg

Cost of Recommendations*Cost of Recommendations*

Folic Acid 1.0 mg 3 cents Vitamin B6 10mg 2 cents Vitamin B12 1.0 mg 6 cents

TOTAL COST: 11 cents/day11 cents x 30 days = $3.30/month

1 Tall Caffe Latte (Starbucks) : $3.30 (plus tax!)

*Cost taken from AWP at UIC Hospital

Future RecommendationsFuture Recommendations

Future research should include various vitamin preparations and their ability to lower specific endpoints, i.e. CVD, cancer, kidney disease, etc.

TOP FIVE HEALTH TOP FIVE HEALTH RESOLUTIONSRESOLUTIONS

5. Stop Smoking4. Exercise More3. Lose Weight2. Become a Better Person

And the #1 Health Resolution is…1. Eat Healthier

10 Essentials for 10 Essentials for Healthy LivingHealthy Living

In order to achieve a quality of life that permits both physical and psychological wellness, it is important to do positive acts that promote both your well being and those around you. Reflect on these 10 essentials for healthy living as you move along your life’s journey.

1. Breathe Deeply

Air is the cornerstone of life. Every moment of every day your body exchanges carbon dioxide for oxygen to keep each cell in your body alive and functioning. A rich supply of oxygen can make the difference between feeling tired and stressed and youthful and focused. Take at least five deep breaths from your abdomen several times per day.

2. Drink Water Water is essential for everything your body does. In fact, you are mostly water! Nutrient absorption, blood flow, respiration, elimination and your ability to see and hear require adequate consumption of pure, clean water. Your body cannot effectively store the water you need throughout the day. Drink water often.

3. Sleep PeacefullySleep is the only time your body has to repair and rejuvenate every organ and system in your body. Sleep deprivation causes cellular damage, and limits the production of enzymes and hormones your body needs to keep your cells healthy, and prevent premature aging. Sleep also has a powerful impact on your emotional health - it eases stress and helps you cope with the ups and downs of your day.

4. Eat NutritiouslyFood has a powerful impact on your body. Every day, food, in large part, determines how you feel and how your body functions. A balanced diet, rich in whole foods, combined with quality nutritional supplements created to meet your specific needs, will give you the energy you need today, and the disease-fighting strength you need to build a healthy future.

Reference: www.trivita.com


5. Enjoy ActivityYour body was created to move - and move often. Activity increases your circulation, speeding oxygen, nutrients and water to your cells. Your lymphatic system requires activity to purge your body of deadly toxins. Activity also triggers your brain to release health-giving hormones and enzymes, which lift your spirit while they bolster your immune system. A small investment in daily moderate activity will enable you to reap tremendous health benefits.

6. Give and Receive LoveAs you give and receive love freely and generously, you will be blessed with meaningful, lifelong relationships and cherished memories that will bring joy in happy times, and strength and peace in difficult times.

7. Be ForgivingIt sounds so simple, and yet can be so difficult. Extending and asking for forgiveness is one of the four principles of emotional health because it is a key to your ability to give and receive love. In its purest form, forgiveness is not an act, but an attitude. As you cultivate the ability to live in a state of forgiveness, your anger, frustration and guilt are replaced with peace, love and acceptance.



8. Practice GratitudeSincere gratitude will lift and inspire you. Recognizing and appreciating all you have empowers you to find and express true joy.

9. Develop AcceptanceWhen you develop the ability to identify and accept the circumstances in your life you cannot change, yet strive to make positive changes whenever and wherever you can, you will discover lasting peace and hope.

10. Develop a Relationship with God You develop a relationship with God the same way you build a relationship with those around you - through sharing and listening. By offering a simple prayer daily, you will enjoy a sense of well being you will not experience in any other way.


REFERENCESREFERENCES

Homocysteine and nutrition: The vitamin connection 1. Aleman G, Tovar AR, Torres N. Homocysteine metabolism and risk of cardiovascular disease: Importance of the nutritious status in folic acid, vitamins B6 and B12. La Revista de Investigacion Clinica. Vol.53,

Issue 2, March-April 2001, pp. 141-151. 2. Brosnan JT, Jacobs RL, et.al. Methylation demand: a key determinant of homocysteine metabolism. Acta Biochim Pol. 2004;51(2):405-13. 3. Selhub J, Jacques PF, et.al. Vitamin Status and intake as primary determinants of HCYemia in an elderly population. JAMA 1993; 270: 2693-2698. 4. Boushey CJ, Beresford SA, et.al. A quantitative assessment of plasma HCY as a risk factor for vascular disease. Probably benefits of increasing folic acid intakes. JAMA 1995;274:1049-57. 5. Rasmussen K, Moller J, et.al. Age- and gender-specific reference intervals for total HCY and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem 1996;42:630-6. 6. Wald DS, Bishop L, Wald NJ, et.al. Randomized trial of folic acid supplementation and serum HCY levels. Arch Intern Med. 2001;161:695-700. 7. Toole JF, Malinow MR, Chambless LE, et.al. Lowering HCY in pts. With ischemic stroke to prevent recurrent stroke, MI, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized

controlled trial. JAMA 2004;291:565-575. 8. Schnyder G, Roffi M, Pin R, et.al. Decreased rate of coronary restenosis after lowering of plasma HCY levels. N Engl J Med. 2001;345:1593-1600. 9. Marcucci R, Zanazzi M, Bertoni E, et.al. Vitamin supplementation reduced the progression of atherosclerosis in hyperHYCemic renal-transplant recipients. Transplantation. 2003;75:1551-1555. 10. Jacques PF, Selhub J, et.al The effect of folic acid fortification on plasma folate and total HCY concentration. N Engl J Med 1999;13:1449-1454. 11. Tucker KL, Selhub K, et.al. Dietary intake pattern related to plasma folate and HCY concentrations in the Framingham Heart Study. J Nutr 1996;126:3025-3031. 12. Food and Drug Administration. Food Standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Federal Register. 1996;61(44):8781-97. 13. Waldmann A, Koschizke JW, et.al. HCY and cobalamin status in German vegans. Public Health Nutr. 2004 May;7(3):467-72. 14. Flood VM, Webb KL, Smith W, et.al. Prevalence of low serum folate, red cell folate, serum vitamin B12 and elevated HCY. Asia Pac J Clin Nutr. 2004;13(Suppl):S85. 15. Strassburg A, Krems C, Luhrmann PM, et.al. Effect of age on plasma HCY concentrations in young and elderly subjects considering serum vitamin concentrations and different lifestyle factors. Int J Vitam Nutr

Res. 2004 Mar;74(2): 129-36. 16. Zeisel SH, Mar MH, et.al. Concentrations of choline-containing compounds and betaine in common foods. J Nutr. 2003 May;133(5): 1302-7. 17. Steenge GR, Verhoef P, Katan MB. Betaine supplementation lowers plasma HCY in healthy men and women. J Nutr. 2003 May;133(5):1291-5. 18. Olthof MR, van Vliet, et.al. Low dose betaine supplementation leads to immediate and long term lowering of plasma HCY in healthy men and women. J Nutr. 2003 Dec;133(12):4135-8. 19. McGregor DO, Dellow WJ, et.al. Betaine supplementation decreases post-methionine HyperHCYemia in chronic renal failure. Kidney Int. 2002 Mar;61(3):1040-6. 20. Riddell, LJ, Chisholm A, et.al. Dietary strategies for lowering HCY concentrations. Am J Clin Nutr. 2000; 71(6): 1448-54. 21. Clarke R, Refsum H, et.al. Screening for vitamin B12 and folate deficiency in older persons. Am J Clin Nutr 2003; 77: 1241-7.

REFERENCESREFERENCES Homocysteine and nutrition: Part B 1. Ward M, McNulty H, et.al. Effect of supplemental methionine on plasma HCY concentrations in healthy men: a preliminary study. Int J Vitam Nutr Res. 2001 Jan;71(1):82-6. 2. Krajvcovivcova-Kudlavckova M, et.al. Nutritional status in adults on an alternative or traditional diet. Cas Lek Cesk. 2001 Mar 15;140(5):142-6. 3. Herrmann W. The importance of hyperhomocysteinemia as a risk factor for diseases: an overview. Clin Chem Lab Med. 2001 Aug;39(8):666-74. 4. Haulrik N, Toubro S, et.al. Effect of protein and methionine intakes on plasma HCY concentrations: a 6-month randomized controlled trial in overweight subjects. Am J Clin Nutr. 2002 Dec;76(6):1202-6. 5. Lourenco R, Camilo ME. Taurine: a conditionally essential amino acid in humans? An overview in health and disease. Nutr Hosp. 2002 Nov-Dec;17(6):262-70. 6. Orts Costa JA, et.al. Cystinuria update: clinical, biochemical and genetic aspects. Ann Med Interna. 2003 Jun;20(6):317-26. 7. Pietrow PK, et.al. Durability of the medical management of cystinuria. J Urol. 2003 Jan;169(1):68070. 8. Kurpad AV, et.al. Daily requirement for total sulfur amino acids of chronically undernourished Indian men. Am J Clin Nutr. 2004 Jul;80(1):95-100. 9. Tamura T, Turnlund JR. Effect of long-term, high copper intake on the concentrations of plasma HCY and B vitamins in young men. Nutrition 2004 Sep;20(9):757-9. 10. Marsh EN. Coenzyme B12 (cobalamin)-dependent enzymes. Essays Biochem. 1999;34: 139-54. 11. Neve J. The nutritional importance and pharmacologic effects of cobalt and vitamin B12 in man. J Pharm Belg. 1991. Jul-Aug;46(4): 271-80. 12. Davis CD, Uthus EO. Dietary folate and selenium affect dimethylhydrazine-induced aberrant crypt formation, global DNA methylation and one-carbon metabolism in rats. J Nutr. 2003 Sep;133(9):2907-14. 13. Gonzalez S, Huerta JM, et.al. Serum selenium is associated with plasma HCY concentration in elderly humans. J Nutr. 2004 Jul;134(7):1736-40. 14. http: www.acu-cell.com/nico2.html. Case Presentations and discussions 1. Ridker P, Brown N, et.al. Established and Emerging Plasma Biomarkers in the Prediction of First Atherosclerotic Events. Circulation. 2004 Jun; 109(25)S: IV 6-19. 2. Warnick GR, Myers GL, et.al. Impact of the third cholesterol report from the ATP panel of the NCEP on the clinical laboratory. Clin Chem. 2002 Jan; 48(1): 11-7. 3. Ridker P, Hennekens CH, et.al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar 23; 342(12): 836-43. 4. American Diabetes Association. Screening for Type 2 Diabetes. Diabetes Care 200; 23: 1563-1580 5. USPSTF, Screening for Coronary Heart Disease: Recommendation Statement. April 6, 2004; 140(7): 569-572. 6. Harrington RA, Becker RC, et.al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004, Sep; 126(3 Supple): 513S-548S. 7. Dwyer K, Ellwood K, et.al. Integration of the continuing survey of food intakes by individuals and the National Health and Nutrition Examination Survey. J Am Diet Assoc. 2001; 101(10):1142-3. 8. Cotton PA, Subar AF, et.al. Dietary Sources of Nutrients Among US Adults, 1994-1996. J Am Diet Assoc. 2004; 104(6): 921-930. 9. Eliason BC, Huebner J, Marchand L. What physicians can learn from consumers of dietary supplements. J Fam Pract. 1999 Jun; 48(6): 459-63. 1. Radimer K, Bindewald B, Hughes J, et.al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol. 2004 Aug 15; 160(4): 339-49. 2. Guirguis-Blake J. Routine vitamin supplementation to prevent cancer and cardiovascular disease. Am Fam Physician. 2004 Aug 1; 70(3): 559-60. 3. Moyad MA. The potential benefits of dietary and/or supplemental calcium and vitamin D. Urol Oncol. 2003 Sep-Oct; 21(5): 384-91. 4. Azzi A. The role of alpha-tocopherol in preventing disease. Eur J Nutr. 2004 Mar; 43 Suppl 1:I/18-25.5. Shekelle PG, Morton SC, et. Al. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med. 2004 Apr; 19(4): 380-9.6. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004 Mar; 79(3): 362-71.7. Meltzer HM, Haugen M, et.al. Vitamin and minerals supplements – required for good health? Tidsskr Nor Laegeforen. 2004 Jun 17; 124(12): 1646-9.

REFERENCESREFERENCES Homocysteine and endothelial effects 1. Maxwell SR, Coronary Artery Disease – free radical damage, antioxidant protection and the role of homocysteine. Basic Res Cardiol.2000;95 Suppl 1:165-71. 2. Ozdemir R, Barutcu I, et.al. Vascular Endothelial Function and Plasma Homocysteine Levels in Behcet’s Disease, Am J Cardiol 2004;94:522-525. 3. Austin RC, Lentz SR, Werstuck GH. Role of HyperHCYemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004 Jul;11 Supple 1:S56-64. 4. Nihei S, Tasaki H, et.al. HyperHCYemia is associated with human coronary atherosclerosis through the reduction of the ratio of endothelium-bound to basal extracellular superoxide dismutase. Circ J.

2004 Sep;68(9):822-8. 5. Schroecksnadel K, Frick B, Winkler C, et.al. HyperHCYemia and immune activation. Clin Chem Lab Med. 2003;41:1438-1443. 6. Tsuda K, Nishio I, Cooke JP, et.al. Asymmetric dimethylarginine and circulatory disorders in postmenopausal women. Circulation. 2004;109:e35. 7. Stuhlinger MC, Oka RK, Graf EE, et.al. Endothelial dysfunction induced by HyperHCYemia. Role of asymmetric dimethylarginine. Circulation. 2003;108:933-938. 8. Splaver A, Lamas GA, Hennekens CH. HCY and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. Am Heart J. 2004 Jul;148(1): 34-40. 9. Zulli A, Widdop RE, Hare DL, et.al. High methionine and cholesterol diet abolished endothelial relaxation. Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1358-63. 10. Nestel P. Metabolic complications of obesity. Asia Pac J Clin Nutr. 2004;13(Supple):S35. Homocysteine and Genetics 1. Yap, S. Classical homocystinuria: Vascular risk and its prevention. J. Inherit. Metab. Dis. 26(2003): 259-265. 2. Gaull GE. Homocystinuria, vitamin B6, and folate: Metabolic interrelationships and clinical significance. J Pediatr 81:1014-1018. 1972. 3. Moat, SJ. Bao, L, et.al. The Molecular Basis of Cystathionine beta-synthase Deficiency in UK and US Patients with Homocystinuria. HUMAN MUTATION. Dec.3, 2003. 4. Zoossmann-Diskin A, Gazit E, et.al. 844ins68 in the CBS gene in Israel and report of its distribution in the world. Anthropol Anz. 2004 Jun;62(2): 147-55. 5. Sokolova J, Janosikova B, et.al. CBS deficiency in Central Europe: discrepancy between biochemical and molecular genetic screening for homocystinuric alleles. Hum Mutat. 2001;18(6):548-9. 6. Refsum H, Fredriksen A, et.al. Birth prevalence of homocystinuria. J Pediatr. 2004 Jun;144(6):830-2. 7. Yap S, Boers GH, et.al. Vascular outcome in patients with homocystinuria due to CBS deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 2001;21:2080-5. 8. Goyette P, Frosst P, et.al. Seven novel mutations in the MTHFR gene and genotype/phenotype correlations in severe MTHFR deficiency. Am J Hum Genet; 56:1052-9. 9. Klerk M, Verhoef P, et.al. MTHFR studies collaboration group MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA; 288:2023-31. 10. McKully KS. Vascular pathology of HCY: implications for pathogenesis of arteriosclerosis. Am J Pathol. 1969; 56: 111-128. 11. Jacques PH, Bostom AG, et.al. Relation between folate status, a common mutation in methylene tetrahydrofolate reductase, and plasma HCY concentration. Circulation. 1996. 93; 7-9. 12. Kluijtmans LA, van den Heuvel LP, et.al. Molecular genetic analysis in mild hyperHYCemia: a common mutation in the MTHFR gene is a genetic risk factor for cardiovascular disease. Am J Hum

Genet. 1996. 58; 1: 35-41. 13. Townsend DM, Tew KD, Tapiero H. Sulfur containing amino acids and human disease. Biomedecine & Pharmacotherapy. 2004 Jan; 58(1): 47-55.

REFERENCESREFERENCES Recommendations regarding homocysteine screening

1. Kidney Int. 2004 Jul;66(1):338-47. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Busch M, Franke S, et.al. 2. Clin Chem Lab Med. 2004 Apr;42(4):408-14. The influence of smoking on plasma HCY and cysteine levels in passive and active smokers. Sobczak A, Wardas W, et.al. 3. Clin Chem. 2004 Aug 19. Screening for Serum Total HCY in Newborn Children. Refsum H, Grindflek AW, Ueland PM, et.al. 4. Eur J Nutr. 2004 Jan 6;:1-3 Abnormal folic acid-HCY metabolism as maternal risk factors for Down Syndrome in Japan. Takamura N, Kondoh T, et.al. 5. Am J Obstet Gynecol. 2004 Jul;191(1):11-17. Marginal maternal vitamin B12 increases the risk of offspring with spina bifida. Groenen PM, Van Rooij IA, Peer PG, et.al. 6. J Clin Endocrinol Metab. 2004 Aug;89(8):3745-51. HyperHCYemia in pts. with Cushing’s Syndrome. Terzolo M, Allasino B, Bosio S, et.al. 7. Eur Heart J.2004 Aug;25(15):1325-9. Plasma HCY in OSA. Svatikova A, Wolk R, Magera MJ, Shamsuzzaman AS, et.al. 8. Perit Dial Int.2004 Jul-Aug;24(4):373-7. Effective HCY-lowering vit B treatment in peritoneal dialysis pts. Righetti M, Tommasi A, et.al. 9. Am J Kidney Dis.2004 Sep;44(3):437-45. Hyper HCYemia and the development of chronic kidney disease in a general population: the Hisayama study. Ninomiya T, Kiyohara Y, et.al. 10. Clin Lab.2004;50(7-8):447-53. Classical and “non-classical” cardiovascular risk factors in Tunisian patients with end stage renal disease: prevalence and association with cardiovascular events. Fellah H, Feki M, Feki H, et.al. 11. Curr Pharm Des.2004;10(22):2719-32. Consequences of elevated HCY during embryonic development and possible modes of action. Brauer PR, Tierney BJ. 12. J Nutr.2004 Sep;134(9):2475S-81S. Alcohol, one-carbon metabolism, and colorectal cancer: recent insights from molecular studies. Giovannucci E. 13. Annu Rev Med 1998;49:31-62. HCY and cardiovascular disease. Refsum H, Ueland PM, et.al. 14. JAMA 1993;270:2693-8. Vitamin status and intake as primary determinants of HCYemia in an elderly population. Selhub J, Jacques PF, et.al. 15. CMAJ.2000 Jul 11;163(1):21-9. Preventive health care, 2000 update: screening and management of hyperHCCYemia for the prevention of CAD evens. The Canadian Task Force on Preventive Health Care. Booth GL, Wang EE. 16. CMAJ.2000 Jul 11;163(1):37-8.HCY: To screen and treat or to wait and see? Genest J, Audelin, MC, Lonn E. 17. Jacques PF, Bostom AG, Wilson PW, et.al. Determinants of plasma total HCY concentration in the Framingham Offspring cohort. Am J Clin Nutr. 2001;73:613-621. 18. Wilson PW. HCY and Coronary Heart Disease: How great is the hazard? JAMA. 2002;288:2042-2043. 19. Nygard O, Nordrehaug JE, Refsum H, et.al. Plasma HCY levels and mortality in patients with CAD. N Engl J Med. 1997;337:230-236. 20. Stanger O, Herrmann W, et.al. Clinical use and rational management of HCY, folic acid, and B vitamins in cardiovascular and thrombotic disease. Z Kardiol.2004 Jun; 93(6):439-53. 21. Fallest-Strobl PC, Koch DD, et.al. HCY: A New Risk Factor for Atherosclerosis. American Family Physician. Oct.15, 1997. Vol.56, No.6. 22. Eikelboom JW, Lonn E, et.al. HCY and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131(5):363-375. 23. Verhoef P. HyperHCYemia and risk of vascular disease in women. Semin Thromb Hemost. 2000;26(3):325-334. 24. American Heart Association. Heart Disease and Stroke Statistics. 2004 Update. Dallas, Tex: American Heart Association; 2003. 25. Mosca L, Appel LJ, Benjamin EJ, et.al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109(5):672-693. 26. Singh H. Selections from current literature: HCY: a modifiable risk factor for cardiovascular disease. Fam Pract 1997;14(4):335-9. 27. Tabas GH, Vanek MS. Is ‘routine’ laboratory testing a thing of the past? Current recommendations regarding screening. Postgraduate Medicine, Vol.105, No.3, March 1999. 28. Malinow MR, Bostom AG, Krauss RM. HCY, diet, and cardiovascular diseases: a statement for health care professionals from the Nutrition Committee, American Heart Association. Circulation 1999;99:178-182. 29. Nilsson M. Cobalamin and folate deficiency. Paradigm shift in screening. Rondel 2004;18. http://www.rondellen.net. 30. O’Callaghan P, Ward D, Graham I. HCY and cardiovascular disease: time to routinely screen and treat? Brit J Cardiology 2003, Vol.10(2): 115-117. 31. Bostom AG, Culleton B. HyperHCYemia in chronic renal disease. J Am Soc Nephrol. 1999;10:891-900. 32. Cravo M, et.al. HyperHCYemia in chronic alcoholism: Relations to folic acid and vitamins B6 and B12 status. Nutrition. 2000;16:296-302. 33. Ray JG, Laskin CA. Folic Acid and HCY metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review. Placenta. 1999;20:519-29. 34. Ellison J, Clark P, et.al. Effect of supplementation with folic acid throughout pregnancy on plasma HCY concentration. Thrombosis Research, Vol.114, Issue 1, 2004. Pp 25-27. 35. Ueland PM, Vollset SE. HCY and Folate in Pregnancy. Clin Chem. 2004;50:1293-1295. 36. Refsum H, Ueland PM, Nygard O, Vollset SE. HCY and cardiovascular disease. Annu Rev Med. 1998;49:31-62. 37. Robinson K, Mayer EL, Miller R, et.al. HyperHCYemia and low pyridoxal phosphate: common and independent reversible risk factors for CAD. Circulation. 1995;92:2825-2830. 38. Boushey CJ, Beresford SA, et.al. A quantitative assessment of plasma HCY as a risk factor for vascular disease. Probably benefits of increasing folic acid intakes. JAMA 1995;274:1049-57. 39. Graham IM, Daly LE, Refsum HM, et.al. Plasma HCY as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775-1781. 40. Zak A, Zeman M. Consequences of moderate hyperhomocysteinemia in the internal medicine. Cas Lek Cesk. 2004;143(6):367-74. 41. Arnadottir M, Hultberg B, Nilsson-Ehle P, et.al. The effect of reduced glomerular filtration rate on plasma total homocysteine concentrations. Scand J Clin Lab Invest 1996;56: 41-46. 42. Selhub J, Jacques PF, Rosenberg IH, et.al. Serum total HCY concentrations in the third national health and nutrition examination survey (1991-94): Population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999;131: 331-339. 43. Stam F, Van Guldener C, et.al. HCY clearance and methylation flux rates in both healthy adults and those with end-stage renal disease: association with S-adenosylhomocysteine. Am J Physiol Renal Physiol. 2004 Aug;287(2):F215-23. 44. Brown, KS, Kluijtmans LAJ, et.al. The 5,10-methylenetetrahydrofolate reductase C677T polymorphism interacts with smoking to increase homocysteine. Atherosclerosis, Vol.174, Issue 2, June 2004. Pp 315-322. 45. Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol. 2002 Jun; 97(6): 1309-18. 46. Panteghini M. The measurement of cardiac markers: where should we focus? Am J Clin Pathol. 2002 Sep; 118(3): 354-61. 47. Booth, G. CMAJ. 2000 July; 163(1): 21-29. 48. Perna AF, Ingrosso D, et.al. HCY metabolism in renal failure. Curr Opin Clin Nutr Metab Care. 2004 Jan; 7(1): 53-7. 49. Skibinska E, Sawicki R, et.al. Kardiol Pol. 2004 Mar;60(3):197-205. 50. Ridker P, Brown N, et.al. Established and Emerging Plasma Biomarkers in the Prediction of First Atherosclerotic Events. Circulation. 2004 Jun; 109(25)S: IV 6-19. 51. Nielsen C, Lang RS. Principles of screening. Med Clin North Am 1999; 83:1323-37. 52. Malinow MR, Bostom AG, et.al. Homocysteine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99: 178-82. 53. Ubbink JB. What is a desirable homocysteine level? In: Carmel R, Jacobsen DW, eds. Homocysteine in health and disease. Cambridge, UK: Cambridge University Press, 2001: 485-90. 54. Christen WG, Ajani UA, et.al. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000; 160: 422-34.

REFERENCESREFERENCES Executive Summary Recommendations 1. Refsum H, Smith DA, et.al. Facts and Recommendations about Total Homocysteine Determinations: An Expert

Opinion. Clin Chem 2004; 50: 3-32. 2. CMAJ.2000 Jul 11;163(1):21-9. Preventive health care, 2000 update: screening and management of

hyperHCCYemia for the prevention of CAD evens. The Canadian Task Force on Preventive Health Care. Booth GL, Wang EE.

3. Selhub J, Jacques PF, et.al. Vitamin Status and intake as primary determinants of HCYemia in an elderly population. JAMA 1993; 270: 2693-2698.

4. Jacques PF, Bostom AG, et.al. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001; 73: 613-21.

5. Klee GG. Cobalamin and folate evaluation; measurement of methylmalonic acid and homocysteine vs. vitamin B12 and folate. Clin Chem 2000; 46: 1277-83.

6. Kang S-S, Wong PWK, et.al. Homocysteinemia due to folate deficiency. Metabolism 1987; 36: 458-62. 7. Nygard O, Refsum H, et.al Coffee consumption and plasma total homocysteine: the Hordaland Homocysteine

Study. Am J Clin Nutr 1997; 65:136-43. 8. Grubben MJ, Boers GH, et.al. Unfiltered coffee increases plasma homocysteine concentrations in healthy

volunteers: a randomized trial. Am J Clin Nutr 2000; 71:480-4.

QUESTIONS?QUESTIONS?

THANK YOU!

HAVE A GREAT DAY!

homocysteine at the crossroads: vitamin status and disease prevention

Documents

homocysteine level4

homocysteine screening

aelevated homocysteine

plasma homocysteine

elevated homocysteine

cardiovascular disease

disease prevention

behcets disease